Skip to content

Septerna, Inc. SEPN Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$3.21M+219%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$18M
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$809K+13,383%
Precigen logo
PrecigenPGEN
$0+100%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$3.3M
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$378.17M

Other financials

Income statement

See full
Revenue$26.5M+12,011%
Operating income-$13.3M+48.7%
Net income-$8.6M+59.8%
EPS (diluted)-$0.19+61.2%

Balance sheet

See full
Cash & equivalents$71.6M-65.9%
Total debt$23.1M-7.7%
Total equity$378.5M+195%
Total assets$569.7M+31.3%

Cash flow

See full
Operating cash flow-$25.6M-9.8%
CapEx$832.0K+118%
Free cash flow-$26.5M-11.5%

Valuation

See full
Market cap$1.62B+319%

Profitability

See full
Operating margin-77.1%-38.4pp
Net margin-49.9%-24.9pp
FCF margin467.9%+243pp

Returns & leverage

See full
Return on equity-12.2%
Debt / equity0.1×
Current ratio4.7×-27.5×

Where this comes from

Reported directly by Septerna, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Septerna, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Septerna, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Septerna, Inc.'s stock issuance proceeds?
Septerna, Inc. (SEPN) reported stock issuance proceeds of $333K in Q1 2026.
How has Septerna, Inc.'s stock issuance proceeds changed year-over-year?
Septerna, Inc.'s stock issuance proceeds increased by 404.5% year-over-year, from $66K to $333K.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.